Meta AnalysisID 464
花生过敏儿童花生口服免疫治疗相关不良事件：系统评价与Meta分析
CRD42018114626
What is the prevalence and type of adverse events associated with the use of peanut oral immunotherapy in children treated for peanut allergy and do these differ according to study type or characteristics?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 464
- Evidence Id
- 9022
- Core Evidence Id
- 9022
- Source Meta Analysis Id
- 439
- Herb2 Meta Analysis Id
- HBMA000439
- Crd Id
- CRD42018114626
- Title
- Adverse events associated with peanut oral immunotherapy in children with peanut allergy: a systematic review and meta-analysis
- Review Question
- What is the prevalence and type of adverse events associated with the use of peanut oral immunotherapy in children treated for peanut allergy and do these differ according to study type or characteristics?
- Study Type Included
- Included studies are restricted to prospective clinical trials of peanut oral immunotherapy that may or may not include randomisation of treatment allocation. Case series and case reports will be excluded from the review.
- Condition Being Studied
- Peanut allergy affects up to 3% of Australian children and in most cases is a life-long condition. Peanut allergy is rarely outgrown and the mainstay of treatment involves complete avoidance of peanuts. Persistent fear of accidental exposure has markedly reduced quality of life of both patients and their families. Desensitisation, while not a cure, is the only proactive and disease-modifying therapeutic approach currently available. Oral immunotherapy (OIT) is the most effective desensitisation method and involves oral administration of escalating doses of peanut followed by a maintenance phase, but this approach can be associated with severe adverse events. This review focuses on evaluating the prevalence and severity of adverse events associated with peanut oral immunotherapy.
- Participant
- Children with peanut allergy receiving oral immunotherapy. Peanut allergy either confirmed by oral food challenge, or based on compelling history and supported by relevant investigations (e.g. IgE, skin prick test results).
- Animal
- Human Disease Modelled
- Intervention
- Studies are restricted to those where at least one treatment arm received peanut oral immunotherapy with or without combination of adjuvant therapies
- Comparator Control
- Included studies are not required to include a comparator group. There is no restriction on what intervention the comparator group received.
- Main Outcome
- Safety of peanut OIT will be assessed according to the frequency, type, severity and seriousness of allergic reactions precipitated by peanut OIT. Measures of effect Where possible, adverse events will be evaluated according to timing relative to peanut oral immunotherapy treatment protocol and stratified according to severity. Severity of reactions is likely to be reported differently across studies, but the following serves as an example of reaction types: A severe adverse reaction is defined as one requiring treatment with adrenaline or hospitalisation. A moderately adverse reaction is defined as a non life threatening systemic reaction necessitating treatment (e.g. oral antihistamine) or medical consultation (e.g. GP visit). A mild adverse reaction is defined as a non-specific reaction that is self-limiting and probably not IgE-mediated (i.e. discomfort, headache, arthralgia, etc). In addition, reasons for withdrawal or exclusion from the studies due to OIT reaction will be assessed.
- Outcome Measure
- Additional Outcome
- Not applicable
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Arachis; Child; Desensitization, Immunologic; Fabaceae; Humans; Peanut Hypersensitivity
- Contact
- Luke Grzeskowiak [email protected]
- Organisational Affiliation
- University of Adelaide https://www.adelaide.edu.au/
- Funding Source
- Other Selection Criteria
- Final Publication
- Grzeskowiak LE, Tao B, Knight E, Cohen-Woods S, Chataway T (2020). Adverse events associated with peanut oral immunotherapy in children – a systematic review and meta-analysis. Scientific Reports. 10: 656, doi: 10.1038/s41598-019-56961-3 https://www.nature.com/articles/s41598-019-56961-3
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Australia
- Review Stage
- Review Completed published
- First Submission Date
- 2018-11-21
- Registration Date
- 2018-12-11
- Anticipated Start Date
- 2018-11-01
- Anticipated Completion Date
- 2019-01-31
- Title Cn
- 花生过敏儿童花生口服免疫治疗相关不良事件：系统评价与Meta分析
- Title En
- Adverse events associated with peanut oral immunotherapy in children with peanut allergy: a systematic review and meta-analysis
- Bilingual Status
- complete